Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

MicroRNA-Based Biomarkers in Lung Cancer: Recent Advances and Potential Applications

Author(s): Dariush Shanehbandi, Milad Asadi, Ensiyeh Seyedrezazadeh, Venus Zafari, Najibeh Shekari, Mortaza Akbari, Leila Rahbarnia and Habib Zarredar*

Volume 23, Issue 7, 2023

Published on: 13 September, 2022

Page: [648 - 667] Pages: 20

DOI: 10.2174/2772432817666220520085719

Price: $65

Abstract

Introduction: MicroRNAs (miRNAs) are a group of small noncoding RNAs (ncRNAs) that post-transcriptionally control the expression of genes by binding and degrading their target mRNAs. miRNAs can function as possible tumor suppressors or oncogenes in various cancers. Lately, miRNAs application as a biomarker (prognosis and diagnosis) for different diseases has gained much attention. miRNAs exist in a stable form in several biological materials, including tissue, plasma, and serum. The noninvasive and easy screening of miRNAs in serum, blood, tissue, and other body fluids and acceptable stability make microRNA a noticeable factor as biomarkers in human malignancies.

Materials and Methods: In this review, we searched some online databases like Web of Science, Embase, and PubMed to find eligible manuscripts up to the end of 2021.

Results: Abnormal expressions of these molecules are associated with the incidence of many illnesses like cancer. Therefore, they are candidates as a molecular tool for noninvasive tumor prognosis and diagnosis. In the current study, we introduce important miRNAs that may be used as prognostic and diagnostic markers in lung cancer patients.

Conclusion: We summarized the latest reports about critical miRNAs related to the diagnosis and prognosis in lung patients.

Keywords: Lung cancer, miRNA, biomarker, diagnosis, prognosis, NSCLC.

« Previous Next »
[1]
Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144(8): 1941-53.
[2]
Zarredar H, Ansarin K, Baradaran B, Ahdi Khosroshahi S, Farajnia S. Potential molecular targets in the treatment of lung cancer using siRNA technology. Cancer Invest 2018; 36(1): 37-58.
[http://dx.doi.org/10.1080/07357907.2017.1416393] [PMID: 29336624]
[3]
Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: A national cancer database survey. J Thorac Oncol 2010; 5(1): 29-33.
[4]
Zarredar H, Ansarin K, Baradaran B, et al. Critical microRNAs in lung cancer: recent advances and potential applications. Anticancer Agents Med Chem 2018; 18(14): 1991-2005.
[http://dx.doi.org/10.2174/1871520618666180808125459] [PMID: 30088452]
[5]
Chen J, Lou J, Yang S, et al. MT1JP inhibits glioma progression via negative regulation of miR-24. Oncol Lett 2020; 19(1): 334-42.
[PMID: 31890049]
[6]
Wu K-L, Tsai Y-M, Lien C-T, Kuo P-L, Hung AJ. The roles of MicroRNA in lung cancer. Int J Mol Sci 2019; 20(7): 1611.
[http://dx.doi.org/10.3390/ijms20071611] [PMID: 30935143]
[7]
Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64(11): 3753-6.
[http://dx.doi.org/10.1158/0008-5472.CAN-04-0637] [PMID: 15172979]
[8]
Manodoro F, Marzec J, Chaplin T, et al. Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia. Blood 2014; 123(13): 2066-74.
[http://dx.doi.org/10.1182/blood-2012-12-469833] [PMID: 24493669]
[9]
Safary A, Moniri R, Hamzeh-Mivehroud M, Dastmalchi S. Highly efficient novel recombinant L-asparaginase with no glutaminase activity from a new halo-thermotolerant Bacillus strain. Bioimpacts 2019; 9(1): 15-23.
[http://dx.doi.org/10.15171/bi.2019.03] [PMID: 30788256]
[10]
Nazarizadeh A, Mohammadi F, Alian F, Faraji P, Nourbakhsh M, Alizadeh-Fanalou S. MicroRNA-154: A novel candidate for diagnosis and therapy of human cancers. OncoTargets Ther 2020; 13: 6603-15.
[http://dx.doi.org/10.2147/OTT.S249268] [PMID: 32753896]
[11]
Lin X, Yang Z, Zhang P, Shao G. miR-154 suppresses non-small cell lung cancer growth in vitro and in vivo. Oncol Rep 2015; 33(6): 3053-60.
[http://dx.doi.org/10.3892/or.2015.3895] [PMID: 25846246]
[12]
Lin X, Yang Z, Zhang P, Liu Y, Shao G. miR-154 inhibits migration and invasion of human non-small cell lung cancer by targeting ZEB2. Oncol Lett 2016; 12(1): 301-6.
[http://dx.doi.org/10.3892/ol.2016.4577] [PMID: 27347142]
[13]
Liu S, Yang Y, Chen L, Liu D, Dong H. MicroRNA-154 functions as a tumor suppressor in non-small cell lung cancer through directly targeting B-cell-specific Moloney murine leukemia virus insertion site 1. Oncol Lett 2018; 15(6): 10098-104.
[http://dx.doi.org/10.3892/ol.2018.8595] [PMID: 29928380]
[14]
Xue Y-J, Fu Y-J, Wang J-H. The inhibitory effect of miR-154-3p on metastasis of non-small cell lung cancer cell lines. TUMOR 2015; 35(5): 498-507.
[15]
Kai Y, Qiang C, Xinxin P, Miaomiao Z, Kuailu L. Decreased miR-154 expression and its clinical significance in human colorectal cancer. World J Surg Oncol 2015; 13(1): 195.
[http://dx.doi.org/10.1186/s12957-015-0607-5] [PMID: 26048406]
[16]
Lingling J, Xiangao J, Guiqing H, Jichan S, Feifei S, Haiyan Z. SNHG20 knockdown suppresses proliferation, migration and invasion, and promotes apoptosis in non-small cell lung cancer through acting as a miR-154 sponge. Biomed Pharmacother 2019; 112: 108648.
[http://dx.doi.org/10.1016/j.biopha.2019.108648] [PMID: 30780105]
[17]
Hong S, Bi M, Chen S, et al. MicroRNA-520f suppresses growth of gastric carcinoma cells by target ATPase family AAA domain-containing protein 2 (ATAD2). Neoplasma 2016; 63(6): 873-9.
[http://dx.doi.org/10.4149/neo_2016_606] [PMID: 27565325]
[18]
Zhou Y, Shen S. MiR-520f acts as a biomarker for the diagnosis of lung cancer. Medicine 2019; 98(30): e16546.
[http://dx.doi.org/10.1097/MD.0000000000016546] [PMID: 31348274]
[19]
Cui J, Li W, Liu G, et al. A novel circular RNA, hsa_circ_0043278, acts as a potential biomarker and promotes non-small cell lung cancer cell proliferation and migration by regulating miR-520f. Artif Cells Nanomed Biotechnol 2019; 47(1): 810-21.
[http://dx.doi.org/10.1080/21691401.2019.1575847] [PMID: 30873868]
[20]
van Kampen JGM, van Hooij O, Jansen CF, et al. miRNA-520f reverses epithelial-to-mesenchymal transition by targeting ADAM9 and TGFBR2. Cancer Res 2017; 77(8): 2008-17.
[http://dx.doi.org/10.1158/0008-5472.CAN-16-2609] [PMID: 28209612]
[21]
Meister J, Schmidt MHH. miR-126 and miR-126*: New players in cancer. ScientificWorldJournal 2010; 10: 2090-100.
[http://dx.doi.org/10.1100/tsw.2010.198] [PMID: 20953557]
[22]
Tao SC, Guo SC, Li M, Ke QF, Guo YP, Zhang CQ. Chitosan wound dressings incorporating exosomes derived from MicroRNA-126 overexpressing synovium mesenchymal stem cells provide sustained release of exosomes and heal full-thickness skin defects in a diabetic rat model. Stem Cells Transl Med 2017; 6(3): 736-47.
[http://dx.doi.org/10.5966/sctm.2016-0275] [PMID: 28297576]
[23]
Tavazoie SF, Alarcón C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451(7175): 147-52.
[http://dx.doi.org/10.1038/nature06487] [PMID: 18185580]
[24]
Tomasetti M, Staffolani S, Nocchi L, et al. Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin Biochem 2012; 45(7-8): 575-81.
[http://dx.doi.org/10.1016/j.clinbiochem.2012.02.009] [PMID: 22374169]
[25]
Ebrahimi F, Gopalan V, Smith RA, Lam AK. miR-126 in human cancers: Clinical roles and current perspectives. Exp Mol Pathol 2014; 96(1): 98-107.
[http://dx.doi.org/10.1016/j.yexmp.2013.12.004] [PMID: 24368110]
[26]
Hamada S, Satoh K, Fujibuchi W, et al. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. MCR 2012; 10(1): 3-10.
[http://dx.doi.org/10.1158/1541-7786.MCR-11-0272] [PMID: 22064652]
[27]
Lin Q, Mao W, Shu Y, et al. A cluster of specified microRNAs in peripheral blood as biomarkers for metastatic non-small-cell lung cancer by stem-loop RT-PCR. J Cancer Res Clin Oncol 2012; 138(1): 85-93.
[http://dx.doi.org/10.1007/s00432-011-1068-z] [PMID: 22009180]
[28]
Cao WJ, Rosenblat JD, Roth NC, et al. Therapeutic angiogenesis by ultrasound-mediated microRNA-126-3p delivery. Arterioscler Thromb Vasc Biol 2015; 35(11): 2401-11.
[http://dx.doi.org/10.1161/ATVBAHA.115.306506] [PMID: 26381870]
[29]
Sun Y, Bai Y, Zhang F, Wang Y, Guo Y, Guo L. miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Biochem Biophys Res Commun 2010; 391(3): 1483-9.
[http://dx.doi.org/10.1016/j.bbrc.2009.12.098] [PMID: 20034472]
[30]
Huang TH, Chu TY. Repression of miR-126 and upregulation of adrenomedullin in the stromal endothelium by cancer-stromal cross talks confers angiogenesis of cervical cancer. Oncogene 2014; 33(28): 3636-47.
[http://dx.doi.org/10.1038/onc.2013.335] [PMID: 24037526]
[31]
Rodríguez M, Silva J, López-Alfonso A, et al. Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer. Genes Chromosomes Cancer 2014; 53(9): 713-24.
[http://dx.doi.org/10.1002/gcc.22181] [PMID: 24764226]
[32]
Song L, Li D, Gu Y, et al. MicroRNA-126 targeting PIK3R2 inhibits NSCLC A549 cell proliferation, migration, and invasion by regulation of PTEN/PI3K/AKT pathway. Clin Lung Cancer 2016; 17(5): e65-75.
[http://dx.doi.org/10.1016/j.cllc.2016.03.012] [PMID: 27236384]
[33]
Shang AQ, Xie YN, Wang J, et al. Predicative values of serum microRNA-22 and microRNA-126 levels for non-small cell lung cancer development and metastasis: A case-control study. Neoplasma 2017; 64(3): 453-9.
[http://dx.doi.org/10.4149/neo_2017_317] [PMID: 28253725]
[34]
Zhu W, Zhou K, Zha Y, et al. Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung cancer. PLoS One 2016; 11(4): e0153046.
[http://dx.doi.org/10.1371/journal.pone.0153046] [PMID: 27093275]
[35]
Kim M-H, Jo EJ, Eom JS, et al. Diagnostic value of microRNAs derived exosomes from bronchoalveolar lavage fluid in early stage lung adenocarcinoma. Chest 2016; 150(4): 703A.
[http://dx.doi.org/10.1016/j.chest.2016.08.798]
[36]
Jusufović E, Rijavec M, Keser D, et al. let-7b and miR-126 are down-regulated in tumor tissue and correlate with microvessel density and survival outcomes in non--small--cell lung cancer. PLoS One 2012; 7(9): e45577.
[http://dx.doi.org/10.1371/journal.pone.0045577] [PMID: 23029111]
[37]
Yang J, Lan H, Huang X, Liu B, Tong Y. MicroRNA-126 inhibits tumor cell growth and its expression level correlates with poor survival in non-small cell lung cancer patients. PLoS One 2012; 7(8): e42978.
[http://dx.doi.org/10.1371/journal.pone.0042978] [PMID: 22900072]
[38]
Zhu X, Li H, Long L, et al. miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin 2012; 44(6): 519-26.
[http://dx.doi.org/10.1093/abbs/gms026] [PMID: 22510476]
[39]
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133(2): 647-58.
[http://dx.doi.org/10.1053/j.gastro.2007.05.022] [PMID: 17681183]
[40]
Bovell LC, Shanmugam C, Putcha BD, et al. The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer. Clin Cancer Res 2013; 19(14): 3955-65.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-3302] [PMID: 23719259]
[41]
Guo Q, Zhang H, Zhang L, et al. MicroRNA-21 regulates non-small cell lung cancer cell proliferation by affecting cell apoptosis via COX-19. Int J Clin Exp Med 2015; 8(6): 8835-41.
[PMID: 26309536]
[42]
Xiong B, Cheng Y, Ma L, Zhang C. MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells. Int J Oncol 2013; 42(1): 219-28.
[http://dx.doi.org/10.3892/ijo.2012.1707] [PMID: 23174819]
[43]
Hatley ME, Patrick DM, Garcia MR, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010; 18(3): 282-93.
[http://dx.doi.org/10.1016/j.ccr.2010.08.013] [PMID: 20832755]
[44]
Chen Z, Liu H, Jin W, Ding Z, Zheng S, Yu Y. Tissue microRNA-21 expression predicted recurrence and poor survival in patients with colorectal cancer - a meta-analysis. OncoTargets Ther 2016; 9: 2615-24.
[PMID: 27226723]
[45]
Cinegaglia NC, Andrade SC, Tokar T, et al. Integrative transcriptome analysis identifies deregulated microRNA-transcription factor networks in lung adenocarcinoma. Oncotarget 2016; 7(20): 28920-34.
[http://dx.doi.org/10.18632/oncotarget.8713] [PMID: 27081085]
[46]
Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009; 15(1): 4-9.
[PMID: 19262443]
[47]
Zhu W, Xu B. MicroRNA-21 identified as predictor of cancer outcome: A meta-analysis. PLoS One 2014; 9(8): e103373.
[http://dx.doi.org/10.1371/journal.pone.0103373] [PMID: 25098165]
[48]
Tian L, Shan W, Zhang Y, Lv X, Li X, Wei C. Up-Regulation of miR-21 expression predicate advanced clinicopathological features and poor prognosis in patients with non-small cell lung cancer. Pathol Oncol Res 2016; 22(1): 161-7.
[http://dx.doi.org/10.1007/s12253-015-9979-7] [PMID: 26453197]
[49]
Liu XG, Zhu WY, Huang YY, et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 2012; 29(2): 618-26.
[http://dx.doi.org/10.1007/s12032-011-9923-y] [PMID: 21516486]
[50]
Sun X, Liu B, Zhao XD, Wang LY, Ji WY. MicroRNA-221 accelerates the proliferation of laryngeal cancer cell line Hep-2 by suppressing Apaf-1. Oncol Rep 2015; 33(3): 1221-6.
[http://dx.doi.org/10.3892/or.2015.3714] [PMID: 25586265]
[51]
Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 2010; 411(11-12): 846-52.
[http://dx.doi.org/10.1016/j.cca.2010.02.074] [PMID: 20223231]
[52]
Gao W, Lu X, Liu L, Xu J, Feng D, Shu Y. MiRNA-21: A biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther 2012; 13(5): 330-40.
[http://dx.doi.org/10.4161/cbt.19073] [PMID: 22237007]
[53]
Stenvold H, Donnem T, Andersen S, et al. High tumor cell expression of microRNA-21 in node positive non-small cell lung cancer predicts a favorable clinical outcome. BMC Clin Pathol 2014; 14(1): 9.
[http://dx.doi.org/10.1186/1472-6890-14-9] [PMID: 24524655]
[54]
de Souza Rocha Simonini P, Breiling A, Gupta N, et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res 2010; 70(22): 9175-84.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-1318] [PMID: 20978187]
[55]
Jonsdottir K, Janssen SR, Da Rosa FC, et al. Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers. PLoS One 2012; 7(11): e48692-2.
[http://dx.doi.org/10.1371/journal.pone.0048692] [PMID: 23144930]
[56]
Jung HM, Patel RS, Phillips BL, Wang H, Cohen DM, Reinhold WC, et al. Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions. Mol Biol Cell 2013; 24(11): 1638-48.
[http://dx.doi.org/10.1091/mbc.e12-12-0891]
[57]
Yeh C-B, Hsieh M-J, Hsieh Y-S, et al. Terminalia catappa exerts antimetastatic effects on hepatocellular carcinoma through transcriptional inhibition of matrix metalloproteinase-9 by modulating NF-κB and AP-1 activity. Evid Based Complement Alternat Med 2012; 2012: 595292.
[http://dx.doi.org/10.1155/2012/595292] [PMID: 23258989]
[58]
Jin Y, Liu Y, Zhang J, et al. The expression of miR-375 is associated with carcinogenesis in three subtypes of lung cancer. PLoS One 2015; 10(12): e0144187.
[http://dx.doi.org/10.1371/journal.pone.0144187] [PMID: 26642205]
[59]
Yu H, Jiang L, Sun C, et al. Decreased circulating miR-375: A potential biomarker for patients with non-small-cell lung cancer. Gene 2014; 534(1): 60-5.
[http://dx.doi.org/10.1016/j.gene.2013.10.024] [PMID: 24404590]
[60]
Li Y, Jiang Q, Xia N, Yang H, Hu C. Decreased expression of microRNA-375 in nonsmall cell lung cancer and its clinical significance. J Int Med Res 2012; 40(5): 1662-9.
[http://dx.doi.org/10.1177/030006051204000505] [PMID: 23206448]
[61]
Lu S, Kong H, Hou Y, et al. Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer. Lung Cancer 2018; 123: 44-51.
[http://dx.doi.org/10.1016/j.lungcan.2018.06.027] [PMID: 30089594]
[62]
Cheng L, Zhan B, Luo P, Wang B. miRNA-375 regulates the cell survival and apoptosis of human non-small cell carcinoma by targeting HER2. Mol Med Rep 2017; 15(3): 1387-92.
[http://dx.doi.org/10.3892/mmr.2017.6112] [PMID: 28098887]
[63]
Mao S, Zheng S, Lu Z, et al. Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1. Transl Lung Cancer Res 2021; 10(7): 3155-72.
[http://dx.doi.org/10.21037/tlcr-21-356] [PMID: 34430355]
[64]
Nadal E, Zhong J, Lin J, et al. A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma. Clin Cancer Res 2014; 20(12): 3107-17.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-3348] [PMID: 24833665]
[65]
Zhao Z, Qin L, Li S. miR-411 contributes the cell proliferation of lung cancer by targeting FOXO1. Tumour Biol 2016; 37(4): 5551-60.
[http://dx.doi.org/10.1007/s13277-015-4425-8] [PMID: 26572153]
[66]
Zhang C, Wang H, Liu X, et al. Oncogenic microRNA-411 promotes lung carcinogenesis by directly targeting suppressor genes SPRY4 and TXNIP. Oncogene 2019; 38(11): 1892-904.
[http://dx.doi.org/10.1038/s41388-018-0534-3] [PMID: 30390072]
[67]
Wang SY, Li Y, Jiang YS, Li RZ. Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer. Eur Rev Med Pharmacol Sci 2017; 21(18): 4092-7.
[PMID: 29028091]
[68]
Zhao W-X, Tang Y-L, Wang W-H, Bao M-W. Up-regulation of circ_0000353 impedes the proliferation and metastasis of non-small cell lung cancer cells via adsorbing miR-411-5p and increasing forkhead box O1. Cancer Biomark 2020; 29(1): 25-37.
[69]
Pal D, Ghatak S, Sen CK. Epigenetic modification of microRNAs: MicroRNA in Regenerative Medicine. Elsevier 2015; pp. 77-109.
[http://dx.doi.org/10.1016/B978-0-12-405544-5.00003-4]
[70]
Zheng L, Qi T, Yang D, et al. microRNA-9 suppresses the proliferation, invasion and metastasis of gastric cancer cells through targeting cyclin D1 and Ets1. PLoS One 2013; 8(1): e55719.
[http://dx.doi.org/10.1371/journal.pone.0055719] [PMID: 23383271]
[71]
Xu T, Liu X, Han L, Shen H, Liu L, Shu Y. Up-regulation of miR-9 expression as a poor prognostic biomarker in patients with non-small cell lung cancer. Clin Transl Oncol 2014; 16(5): 469-75.
[http://dx.doi.org/10.1007/s12094-013-1106-1] [PMID: 24019037]
[72]
Zhou X, Marian C, Makambi KH, et al. MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status. PLoS One 2012; 7(6): e39011.
[http://dx.doi.org/10.1371/journal.pone.0039011] [PMID: 22723919]
[73]
Han L, Wang W, Ding W, Zhang L. MiR-9 is involved in TGF-β1-induced lung cancer cell invasion and adhesion by targeting SOX7. J Cell Mol Med 2017; 21(9): 2000-8.
[http://dx.doi.org/10.1111/jcmm.13120] [PMID: 28266181]
[74]
Wang H, Wu Q, Zhang Y, Zhang H-N, Wang Y-B, Wang W. TGF-β1-induced epithelial-mesenchymal transition in lung cancer cells involves upregulation of miR-9 and downregulation of its target, E-cadherin. Cell Mol Biol Lett 2017; 22(1): 22-2.
[http://dx.doi.org/10.1186/s11658-017-0053-1] [PMID: 29118814]
[75]
Li G, Wu F, Yang H, Deng X, Yuan Y. MiR-9-5p promotes cell growth and metastasis in non-small cell lung cancer through the repression of TGFBR2. Biomed Pharmacother 2017; 96: 1170-8.
[http://dx.doi.org/10.1016/j.biopha.2017.11.105] [PMID: 29239816]
[76]
Muraoka T, Soh J, Toyooka S, et al. Impact of aberrant methylation of microRNA-9 family members on non-small cell lung cancers. Mol Clin Oncol 2013; 1(1): 185-9.
[http://dx.doi.org/10.3892/mco.2012.18] [PMID: 24649145]
[77]
Bediaga NG, Davies MP, Acha-Sagredo A, et al. A microRNA-based prediction algorithm for diagnosis of non-small lung cell carcinoma in minimal biopsy material. Br J Cancer 2013; 109(9): 2404-11.
[http://dx.doi.org/10.1038/bjc.2013.623] [PMID: 24113142]
[78]
Chen X, Zhu L, Ma Z, et al. Oncogenic miR-9 is a target of erlotinib in NSCLCs. Sci Rep 2015; 5(1): 17031.
[http://dx.doi.org/10.1038/srep17031] [PMID: 26593208]
[79]
Wang K, Xu K, Leng X, Han Y, Fang Q. miRNA-9 inhibits proliferation and migration of lung squamous cell carcinoma cells by regulating NRSF/EGFR. Technol Cancer Res Treat 2020; 19: 1533033820945807.
[http://dx.doi.org/10.1177/1533033820945807] [PMID: 32772818]
[80]
Rizos E, Siafakas N, Katsantoni E, et al. Let-7, mir-98 and mir-183 as biomarkers for cancer and schizophrenia. PLoS One 2015; 10(4): e0123522.
[http://dx.doi.org/10.1371/journal.pone.0123522] [PMID: 25856466]
[81]
Roberts SA, Kaiser UB. GENETICS IN ENDOCRINOLOGY: Genetic etiologies of central precocious puberty and the role of imprinted genes. Eur J Endocrinol 2020; 183(4): R107-17.
[http://dx.doi.org/10.1530/EJE-20-0103] [PMID: 32698138]
[82]
Wang K, Dong L, Fang Q, Xia H, Hou X. Low serum miR-98 as an unfavorable prognostic biomarker in patients with non-small cell lung cancer. Cancer Biomark 2017; 20(3): 283-8.
[http://dx.doi.org/10.3233/CBM-170124] [PMID: 28946561]
[83]
Ni R, Huang Y, Wang J. miR-98 targets ITGB3 to inhibit proliferation, migration, and invasion of non-small-cell lung cancer. OncoTargets Ther 2015; 8: 2689-97.
[PMID: 26445551]
[84]
Yang G, Zhang X, Shi J. MiR-98 inhibits cell proliferation and invasion of non-small cell carcinoma lung cancer by targeting PAK1. Int J Clin Exp Med 2015; 8(11): 20135-45.
[PMID: 26884926]
[85]
Du L, Schageman JJ, Subauste MC, et al. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res 2009; 7(8): 1234-43.
[http://dx.doi.org/10.1158/1541-7786.MCR-08-0507] [PMID: 19671678]
[86]
Jiang F, Yu Q, Chu Y, et al. MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1. Int J Oncol 2019; 54(1): 128-38.
[PMID: 30387848]
[87]
Deng Z-Q, Yin J-Y, Tang Q, et al. Over-expression of miR-98 in FFPE tissues might serve as a valuable source for biomarker discovery in breast cancer patients. Int J Clin Exp Pathol 2014; 7(3): 1166-71.
[PMID: 24696733]
[88]
Wu F, Mo Q, Wan X, Dan J, Hu H. NEAT1/hsa-mir-98-5p/MAPK6 axis is involved in non-small-cell lung cancer development. J Cell Biochem 2019; 120(3): 2836-46.
[http://dx.doi.org/10.1002/jcb.26442] [PMID: 29095526]
[89]
Zhou H, Huang Z, Chen X, Chen S. miR-98 inhibits expression of TWIST to prevent progression of non-small cell lung cancers. Biomed Pharmacother 2017; 89: 1453-61.
[http://dx.doi.org/10.1016/j.biopha.2017.01.012] [PMID: 28415380]
[90]
Liu W, Xiao P, Wu H, Wang L, Kong D, Micro YuF. RNA-98 plays a suppressive role in non-small cell lung cancer through inhibition of SALL4 protein expression. Oncol Res 2017; 25(6): 975-88.
[http://dx.doi.org/10.3727/096504016X14791726591124]
[91]
Tang Y, Wu L, Zhao M, et al. LncRNA SNHG4 promotes the proliferation, migration, invasiveness, and epithelial-mesenchymal transition of lung cancer cells by regulating miR-98-5p. Biochem Cell Biol 2019; 97(6): 767-76.
[http://dx.doi.org/10.1139/bcb-2019-0065] [PMID: 31220419]
[92]
ElKhouly AM, Youness RA, Gad MZ. MicroRNA-486-5p and microRNA-486-3p: Multifaceted pleiotropic mediators in oncological and non-oncological conditions. Noncoding RNA Res 2020; 5(1): 11-21.
[http://dx.doi.org/10.1016/j.ncrna.2020.01.001] [PMID: 31993547]
[93]
Wang J, Tian X, Han R, et al. Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene 2014; 33(9): 1181-9.
[http://dx.doi.org/10.1038/onc.2013.42] [PMID: 23474761]
[94]
Tian F, Wang J, Ouyang T, et al. MiR-486-5p serves as a good biomarker in nonsmall cell lung cancer and suppresses cell growth with the involvement of a target PIK3R1. Front Genet 2019; 10: 688-8.
[http://dx.doi.org/10.3389/fgene.2019.00688] [PMID: 31402930]
[95]
Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010; 28(10): 1721-6.
[http://dx.doi.org/10.1200/JCO.2009.24.9342] [PMID: 20194856]
[96]
Pang W, Tian X, Bai F, et al. Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer. Mol Cancer 2014; 13(1): 240.
[http://dx.doi.org/10.1186/1476-4598-13-240] [PMID: 25342548]
[97]
Tian F, Shen Y, Chen Z, Li R, Lu J, Ge Q. Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer. Gene 2016; 591(2): 338-43.
[http://dx.doi.org/10.1016/j.gene.2016.06.014] [PMID: 27291819]
[98]
Chen T, Zhu J, Cai T, et al. Suppression of non-small cell lung cancer migration and invasion by hsa-miR-486-5p via the TGF-β/SMAD2 signaling pathway. J Cancer 2019; 10(24): 6014-24.
[http://dx.doi.org/10.7150/jca.35017] [PMID: 31762811]
[99]
Jin B, Jin H, Wu HB, Xu JJ, Li B. Long non-coding RNA SNHG15 promotes CDK14 expression via miR-486 to accelerate non-small cell lung cancer cells progression and metastasis. J Cell Physiol 2018; 233(9): 7164-72.
[http://dx.doi.org/10.1002/jcp.26543] [PMID: 29630731]
[100]
Wang A, Zhu J, Li J, et al. Downregulation of KIAA1199 by miR-486-5p suppresses tumorigenesis in lung cancer. Cancer Med 2020; 9(15): 5570-86.
[http://dx.doi.org/10.1002/cam4.3210] [PMID: 32519472]
[101]
Tian F, Ouyang T, Lu N, Shen Y, Bai Y, Xie X, et al. MiR-486-5p serves as a good biomarker in NSCLC and suppresses cell growth with the involvement of a target-PIK3R1. Front Genet 2019; 10: 688.
[http://dx.doi.org/10.3389/fgene.2019.00688] [PMID: 31402930]
[102]
Xing Z, Zhang Z, Gao Y, et al. The lncRNA LINC01194/miR-486-5p axis facilitates malignancy in non-small cell lung cancer via regulating CDK4. OncoTargets Ther 2020; 13: 3151-63.
[http://dx.doi.org/10.2147/OTT.S235037] [PMID: 32346298]
[103]
Yu S, Geng S, Hu Y. miR-486-5p inhibits cell proliferation and invasion through repressing GAB2 in non-small cell lung cancer. Oncol Lett 2018; 16(3): 3525-30.
[http://dx.doi.org/10.3892/ol.2018.9053] [PMID: 30127957]
[104]
Li W, Wang Y, Zhang Q, et al. MicroRNA-486 as a biomarker for early diagnosis and recurrence of non-small cell lung cancer. PLoS One 2015; 10(8): e0134220.
[http://dx.doi.org/10.1371/journal.pone.0134220] [PMID: 26237047]
[105]
Ouzounova M, Vuong T, Ancey P-B, et al. MicroRNA miR-30 family regulates non-attachment growth of breast cancer cells. BMC Genomics 2013; 14(1): 139.
[http://dx.doi.org/10.1186/1471-2164-14-139] [PMID: 23445407]
[106]
Jiang L-H, Zhang H-D, Tang J-H. MiR-30a: A novel biomarker and potential therapeutic target for cancer. Journal of Oncology 2018; 2018
[http://dx.doi.org/10.1155/2018/5167829]
[107]
Zhong Z, Xia Y, Wang P, Liu B, Chen Y. Low expression of microRNA-30c promotes invasion by inducing epithelial mesenchymal transition in non-small cell lung cancer. Mol Med Rep 2014; 10(5): 2575-9.
[http://dx.doi.org/10.3892/mmr.2014.2494] [PMID: 25119247]
[108]
Zhong K, Chen K, Han L, Li B. MicroRNA-30b/c inhibits non-small cell lung cancer cell proliferation by targeting Rab18. BMC Cancer 2014; 14(1): 703.
[http://dx.doi.org/10.1186/1471-2407-14-703] [PMID: 25249344]
[109]
Wen XP, Ma HL, Zhao LY, Zhang W, Dang CX. MiR-30a suppresses non-small cell lung cancer progression through AKT signaling pathway by targeting IGF1R. Cell Mol Biol 2015; 61(2): 78-85.
[PMID: 26025408]
[110]
Luan N, Wang Y, Liu X. Absent expression of miR-30a promotes the growth of lung cancer cells by targeting MEF2D. Oncol Lett 2018; 16(1): 1173-9.
[http://dx.doi.org/10.3892/ol.2018.8719] [PMID: 29963192]
[111]
Xu X, Jin S, Ma Y, et al. miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression. J Mol Med 2017; 95(8): 861-71.
[http://dx.doi.org/10.1007/s00109-017-1539-z] [PMID: 28487996]
[112]
Kumarswamy R, Mudduluru G, Ceppi P, et al. MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer 2012; 130(9): 2044-53.
[http://dx.doi.org/10.1002/ijc.26218] [PMID: 21633953]
[113]
Baffa R, Fassan M, Volinia S, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009; 219(2): 214-21.
[http://dx.doi.org/10.1002/path.2586] [PMID: 19593777]
[114]
Świtlik W, Karbownik MS, Suwalski M, Kozak J, Szemraj J. miR-30a-5p together with miR-210-3p as a promising biomarker for non-small cell lung cancer: A preliminary study. Dis Markers 2018; 21(2): 479-88.
[http://dx.doi.org/10.3233/CBM-170767] [PMID: 29103030]
[115]
Zhu J, Zeng Y, Li W, et al. CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer. Mol Cancer 2017; 16(1): 34-4.
[http://dx.doi.org/10.1186/s12943-017-0591-1] [PMID: 28158983]
[116]
Sun L, Chen Y, Su Q, et al. Increased plasma miRNA-30a as a biomarker for non-small cell lung cancer. Med Sci Monit 2016; 22: 647-55.
[http://dx.doi.org/10.12659/MSM.897330] [PMID: 26918265]
[117]
Wang F, Meng F, Wong SCC, Cho WCS, Yang S, Chan LWC. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer. Ther Adv Respir Dis 2020; 14: 1753466620915156.
[http://dx.doi.org/10.1177/1753466620915156] [PMID: 32552611]
[118]
Zarredar H, Farajnia S, Ansarin K, Baradaran B, Aria M, Asadi M. Synergistic effect of novel EGFR inhibitor AZD8931 and p38α siRNA in lung adenocarcinoma cancer cells. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 2019; 19(5): 638-44.
[119]
Li J, Xu X, Wei C, Liu L, Wang T. Long noncoding RNA NORAD regulates lung cancer cell proliferation, apoptosis, migration, and invasion by the miR-30a-5p/ADAM19 axis. Int J Clin Exp Pathol 2020; 13(1): 1-13.
[PMID: 32055266]
[120]
Tang R, Liang L, Luo D, et al. Downregulation of MiR-30a is associated with poor prognosis in lung cancer. Med Sci Monit 2015; 21: 2514-20.
[http://dx.doi.org/10.12659/MSM.894372] [PMID: 26305739]
[121]
Wu W, Zhao Y, Gao E, et al. LncRNA DLEU2 accelerates the tumorigenesis and invasion of non-small cell lung cancer by sponging miR-30a-5p. J Cell Mol Med 2020; 24(1): 441-50.
[http://dx.doi.org/10.1111/jcmm.14749] [PMID: 31721438]
[122]
Li X, Liu J, Liu M, Xia C, Zhao Q. The Lnc LINC00461/miR-30a-5p facilitates progression and malignancy in non-small cell lung cancer via regulating ZEB2. Cell Cycle 2020; 19(7): 825-36.
[http://dx.doi.org/10.1080/15384101.2020.1731946] [PMID: 32106756]
[123]
Ma YS, Yu F, Zhong XM, Lu GX. miR-30 family reduction maintains self-renewal and promotes tumorigenesis in NSCLC-Initiating cells by targeting oncogene TM4SF1. Mol Ther 2018; 26(12): 2751-65.
[124]
Yan J, Ma C, Gao Y. MicroRNA-30a-5p suppresses epithelial-mesenchymal transition by targeting profilin-2 in high invasive non-small cell lung cancer cell lines. Oncol Rep 2017; 37(5): 3146-54.
[http://dx.doi.org/10.3892/or.2017.5566] [PMID: 28405690]
[125]
Jiang X, Yuan Y, Tang L, et al. Identification and validation prognostic impact of MiRNA-30a-5p in lung adenocarcinoma. Front Oncol 2022; 12: 470.
[126]
Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009; 27(12): 2030-7.
[http://dx.doi.org/10.1200/JCO.2008.19.4134] [PMID: 19273703]
[127]
Adachi R, Horiuchi S, Sakurazawa Y, Hasegawa T, Sato K, Sakamaki T. ErbB2 down-regulates microRNA-205 in breast cancer. Biochem Biophys Res Commun 2011; 411(4): 804-8.
[http://dx.doi.org/10.1016/j.bbrc.2011.07.033] [PMID: 21787752]
[128]
Cai J, Fang L, Huang Y, et al. miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. Cancer Res 2013; 73(17): 5402-15.
[http://dx.doi.org/10.1158/0008-5472.CAN-13-0297] [PMID: 23856247]
[129]
Duan B, Guo T, Sun H, Cai R, Rui Q, Xi Z. miR-205 as a biological marker in non-small cell lung cancer. Biomed Pharmacother 2017; 91: 823-30.
[http://dx.doi.org/10.1016/j.biopha.2017.04.086] [PMID: 28501009]
[130]
Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, Westra WH. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 2010; 16(2): 610-9.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-2638] [PMID: 20068099]
[131]
Li J-H, Sun S-S, Li N, Lv P, Xie S-Y, Wang P-Y. MiR-205 as a promising biomarker in the diagnosis and prognosis of lung cancer. Oncotarget 2017; 8(54): 91938-49.
[http://dx.doi.org/10.18632/oncotarget.20262] [PMID: 29190887]
[132]
Dong L, Li G, Li Y, Zhu Z. Upregulation of long noncoding RNA GAS5 inhibits lung cancer cell proliferation and metastasis via miR-205/PTEN axis. Med Sci Monit 2019; 25: 2311-9.
[http://dx.doi.org/10.12659/MSM.912581] [PMID: 30926767]
[133]
Jiang M, Zhang P, Hu G, et al. Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients. Mol Cell Biochem 2013; 383(1-2): 67-75.
[http://dx.doi.org/10.1007/s11010-013-1755-y] [PMID: 23881177]
[134]
Xu L-B, Xiong J, Zhang Y-H, et al. miR-205-3p promotes lung cancer progression by targeting APBB2. Mol Med Rep 2021; 24(2): 1-11.
[http://dx.doi.org/10.3892/mmr.2021.12227]
[135]
Zhao YL, Zhang JX, Yang JJ, et al. MiR-205-5p promotes lung cancer progression and is valuable for the diagnosis of lung cancer. Thorac Cancer 2022; 13(6): 832-43.
[http://dx.doi.org/10.1111/1759-7714.14331] [PMID: 35076182]
[136]
Sromek M, Glogowski M, Chechlinska M, et al. Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection. Cell Oncol 2017; 40(5): 529-36.
[http://dx.doi.org/10.1007/s13402-017-0334-8] [PMID: 28634901]
[137]
Zheng DH, Wang X, Lu LN, et al. MiR-638 serves as a tumor suppressor by targeting HOXA9 in glioma. Eur Rev Med Pharmacol Sci 2018; 22(22): 7798-806.
[PMID: 30536324]
[138]
Li D, Wang Q, Liu C, et al. Aberrant expression of miR-638 contributes to benzo(a)pyrene-induced human cell transformation. Toxicol Sci 2012; 125(2): 382-91.
[http://dx.doi.org/10.1093/toxsci/kfr299] [PMID: 22048643]
[139]
Wang F, Lou JF, Cao Y, et al. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy. Exp Mol Med 2015; 47(5): e162-2.
[http://dx.doi.org/10.1038/emm.2015.17] [PMID: 25952770]
[140]
Xia Y, Wu Y, Liu B, Wang P, Chen Y. Downregulation of miR-638 promotes invasion and proliferation by regulating SOX2 and induces EMT in NSCLC. FEBS Lett 2014; 588(14): 2238-45.
[http://dx.doi.org/10.1016/j.febslet.2014.05.002] [PMID: 24842609]
[141]
Fang K, Chen X, Qiu F, Xu J, Xiong H, Zhang Z. Serum-Derived exosomes-mediated circular rna arhgap10 modulates the progression of non-small-cell lung cancer through the miR-638/FAM83F axis. Cancer Biother Radiopharm 2022; 37(2): 96-110.
[PMID: 32783691]
[142]
Ma K, Pan X, Fan P, et al. Loss of miR-638 in vitro promotes cell invasion and a mesenchymal-like transition by influencing SOX2 expression in colorectal carcinoma cells. Mol Cancer 2014; 13(1): 118.
[http://dx.doi.org/10.1186/1476-4598-13-118] [PMID: 24885288]
[143]
Wu X, Bhayani MK, Dodge CT, et al. Coordinated targeting of the EGFR signaling axis by microRNA-27a*. Oncotarget 2013; 4(9): 1388-98.
[http://dx.doi.org/10.18632/oncotarget.1239] [PMID: 23963114]
[144]
Wulfken LM, Moritz R, Ohlmann C, et al. MicroRNAs in renal cell carcinoma: Diagnostic implications of serum miR-1233 levels. PLoS One 2011; 6(9): e25787.
[http://dx.doi.org/10.1371/journal.pone.0025787] [PMID: 21984948]
[145]
Jin JJ, Liu YH, Si JM, Ni R, Wang J. Overexpression of miR-1290 contributes to cell proliferation and invasion of non small cell lung cancer by targeting interferon regulatory factor 2. Int J Biochem Cell Biol 2018; 95: 113-20.
[http://dx.doi.org/10.1016/j.biocel.2017.12.017] [PMID: 29275213]
[146]
Xiao X, Yang D, Gong X, Mo D, Pan S, Xu J. miR-1290 promotes lung adenocarcinoma cell proliferation and invasion by targeting SOCS4. Oncotarget 2018; 9(15): 11977-88.
[http://dx.doi.org/10.18632/oncotarget.24046] [PMID: 29552286]
[147]
Zhang WC, Chin TM, Yang H, et al. Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. Nat Commun 2016; 7(1): 11702.
[http://dx.doi.org/10.1038/ncomms11702] [PMID: 27325363]
[148]
Mo D, Gu B, Gong X, et al. miR-1290 is a potential prognostic biomarker in non-small cell lung cancer. J Thorac Dis 2015; 7(9): 1570-9.
[PMID: 26543604]
[149]
Wu Y, Wei J, Zhang W, Xie M, Wang X, Xu J. Serum exosomal miR-1290 is a potential biomarker for lung adenocarcinoma. OncoTargets Ther 2020; 13: 7809-18.
[http://dx.doi.org/10.2147/OTT.S263934] [PMID: 32801784]
[150]
Kim G, An HJ, Lee MJ, et al. Hsa-miR-1246 and hsa-miR-1290 are associated with stemness and invasiveness of non-small cell lung cancer. Lung Cancer 2016; 91: 15-22.
[http://dx.doi.org/10.1016/j.lungcan.2015.11.013] [PMID: 26711929]
[151]
Zhang H, Guo J, Mao L, et al. Up-regulation of miR-24-1-5p is involved in the chemoprevention of colorectal cancer by black raspberry anthocyanins. Br J Nutr 2019; 122(5): 518-26.
[http://dx.doi.org/10.1017/S0007114518003136] [PMID: 30375302]
[152]
Wang S, Zhang R, Claret FX, Yang H. Involvement of microRNA-24 and DNA methylation in resistance of nasopharyngeal carcinoma to ionizing radiation. Mol Cancer Ther 2014; 13(12): 3163-74.
[http://dx.doi.org/10.1158/1535-7163.MCT-14-0317] [PMID: 25319395]
[153]
Wang XH, Gan CZ, Xie JY. Inhibition of miR-24 suppresses malignancy of human non-small cell lung cancer cells by targeting WWOX in vitro and in vivo. Thorac Cancer 2018; 9(12): 1583-93.
[http://dx.doi.org/10.1111/1759-7714.12824] [PMID: 30307120]
[154]
Liu Z, Jiang L, Zhang G, Li S, Jiang X. MiR-24 promotes migration and invasion of non-small cell lung cancer by targeting ZNF367. J BUON 2018; 23(5): 1413-9.
[155]
Zhao G, Liu L, Zhao T, et al. Upregulation of miR-24 promotes cell proliferation by targeting NAIF1 in non-small cell lung cancer. Tumour Biol 2015; 36(5): 3693-701.
[http://dx.doi.org/10.1007/s13277-014-3008-4] [PMID: 25725584]
[156]
Du WW, Fang L, Li M, et al. MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling. J Cell Sci 2013; 126(Pt 6): 1440-53.
[http://dx.doi.org/10.1242/jcs.118299] [PMID: 23418360]
[157]
Akbarzadeh Khiavi M, Safary A, Barar J, Ajoolabady A, Somi MH, Omidi Y. Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer. Cell Mol Life Sci 2020; 77(6): 997-1019.
[PMID: 31563999]
[158]
Xie L, Wang T, Yu S, et al. Cell-free miR-24 and miR-30d, potential diagnostic biomarkers in malignant effusions. Clin Biochem 2011; 44(2-3): 216-20.
[http://dx.doi.org/10.1016/j.clinbiochem.2010.11.002] [PMID: 21093424]
[159]
Franchina T, Amodeo V, Bronte G, et al. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol 2014; 229(1): 97-9.
[PMID: 23794259]
[160]
Chen W, Fu W, Deng Q, et al. Multiple metals exposure and chromosome damage: Exploring the mediation effects of microRNAs and their potentials in lung carcinogenesis. Environ Int 2019; 122: 291-300.
[http://dx.doi.org/10.1016/j.envint.2018.11.020] [PMID: 30455104]
[161]
Yan L, Ma J, Zhu Y, et al. miR-24-3p promotes cell migration and proliferation in lung cancer by targeting SOX7. J Cell Biochem 2018; 119(5): 3989-98.
[http://dx.doi.org/10.1002/jcb.26553] [PMID: 29231262]
[162]
Zhou Q, Long L, Zhou T, Tian J, Zhou B. Demethylation of MicroRNA-124a genes attenuated proliferation of rheumatoid arthritis derived fibroblast-like synoviocytes and synthesis of tumor necrosis factor-α. PLoS One 2016; 11(11): e0164207.
[http://dx.doi.org/10.1371/journal.pone.0164207] [PMID: 27824863]
[163]
Luo P, Yang Q, Cong LL, et al. Identification of miR-124a as a novel diagnostic and prognostic biomarker in non-small cell lung cancer for chemotherapy. Mol Med Rep 2017; 16(1): 238-46.
[http://dx.doi.org/10.3892/mmr.2017.6595] [PMID: 28534972]
[164]
Sun Y, Ai X, Shen S, Lu S. NF-κB-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10. Oncotarget 2015; 6(10): 8244-54.
[http://dx.doi.org/10.18632/oncotarget.3135] [PMID: 25749519]
[165]
Yang Q, Wan L, Xiao C, et al. Inhibition of LHX2 by miR-124 suppresses cellular migration and invasion in non-small cell lung cancer. Oncol Lett 2017; 14(3): 3429-36.
[http://dx.doi.org/10.3892/ol.2017.6607] [PMID: 28927097]
[166]
Zarredar H, Pashapour S, Farajnia S, et al. Targeting the KRAS, p38α and NF-κB in lung adenocarcinoma cancer cells: The effect of combining RNA interferences with a chemical inhibitor. J Cell Biochem 2019; 120(6): 10670-7.
[http://dx.doi.org/10.1002/jcb.28357] [PMID: 30656741]
[167]
Li S, Mei Z, Hu HB, Zhang X. The lncRNA MALAT1 contributes to non-small cell lung cancer development via modulating miR-124/STAT3 axis. J Cell Physiol 2018; 233(9): 6679-88.
[http://dx.doi.org/10.1002/jcp.26325] [PMID: 29215698]
[168]
Aftabi Y, Ansarin K, Shanehbandi D, et al. Long non-coding RNAs as potential biomarkers in the prognosis and diagnosis of lung cancer: A review and target analysis. IUBMB Life 2021; 73(2): 307-27.
[http://dx.doi.org/10.1002/iub.2430] [PMID: 33369006]
[169]
Wang M, Meng B, Liu Y, Yu J, Chen Q, Liu Y. MiR-124 inhibits growth and enhances radiation-induced apoptosis in non-small cell lung cancer by inhibiting STAT3. Cell Physiol Biochem 2017; 44(5): 2017-28.
[http://dx.doi.org/10.1159/000485907] [PMID: 29237164]
[170]
Hu FY, Cao XN, Xu QZ, et al. miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer. J Huazhong University of Science and Technology 2016; 36(6): 839-45.
[http://dx.doi.org/10.1007/s11596-016-1672-x] [PMID: 27924500]
[171]
Liu T, Zhu J, Du W, et al. AKT2 drives cancer progression and is negatively modulated by miR-124 in human lung adenocarcinoma. Respir Res 2020; 21(1): 227.
[http://dx.doi.org/10.1186/s12931-020-01491-0] [PMID: 32873299]
[172]
Qi MM, Ge F, Chen XJ, Tang C, Ma J. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3. Eur Rev Med Pharmacol Sci 2019; 23(12): 5242-50.
[PMID: 31298375]
[173]
Yu W, Peng W, Jiang H, Sha H, Li J. LncRNA HOXA11-AS promotes proliferation and invasion by targeting miR-124 in human non-small cell lung cancer cells. Tumour Biol 2017; 39(10): 1010428317721440.
[http://dx.doi.org/10.1177/1010428317721440] [PMID: 29034803]
[174]
Tan X, Zhang C, Gao W, Sun B, Jiang B, Song P. Overexpression of microRNA-124-5p sensitizes non-small cell lung cancer cells to treatment with 5-fluorouracil via AEG-1 regulation. Oncol Lett 2021; 21(1): 5.
[PMID: 33240411]
[175]
Xiao H. MiR-7-5p suppresses tumor metastasis of non-small cell lung cancer by targeting NOVA2. Cell Mol Biol Lett 2019; 24(1): 60.
[http://dx.doi.org/10.1186/s11658-019-0188-3] [PMID: 31832068]
[176]
Vera O, Jimenez J, Pernia O, et al. DNA Methylation of miR-7 is a mechanism involved in platinum response through MAFG overexpression in cancer cells. Theranostics 2017; 7(17): 4118-34.
[http://dx.doi.org/10.7150/thno.20112] [PMID: 29158814]
[177]
Liu H, Wu X, Huang J, Peng J, Guo L. miR-7 modulates chemoresistance of small cell lung cancer by repressing MRP1/ABCC1. Int J Exp Pathol 2015; 96(4): 240-7.
[http://dx.doi.org/10.1111/iep.12131] [PMID: 26108539]
[178]
Rodríguez-Antolín C, Felguera-Selas L, Pernía O, et al. miR-7 methylation as a biomarker to predict poor survival in early-stage non-small cell lung cancer patients. Cell Biosci 2019; 9(1): 63-3.
[http://dx.doi.org/10.1186/s13578-019-0326-7] [PMID: 31406565]
[179]
Lai J, Yang H, Zhu Y, Ruan M, Huang Y, Zhang Q. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer. BMC Cancer 2019; 19(1): 602.
[http://dx.doi.org/10.1186/s12885-019-5798-7] [PMID: 31215481]
[180]
Li J, Zheng Y, Sun G, Xiong S. Restoration of miR-7 expression suppresses the growth of Lewis lung cancer cells by modulating epidermal growth factor receptor signaling. Oncol Rep 2014; 32(6): 2511-6.
[http://dx.doi.org/10.3892/or.2014.3519] [PMID: 25334070]
[181]
Zhang X, Yang D, Wei Y. Overexpressed CDR1as functions as an oncogene to promote the tumor progression via miR-7 in non-small-cell lung cancer. OncoTargets Ther 2018; 11: 3979-87.
[http://dx.doi.org/10.2147/OTT.S158316] [PMID: 30022841]
[182]
Su C, Han Y, Zhang H, et al. CiRS-7 targeting miR-7 modulates the progression of non-small cell lung cancer in a manner dependent on NF-κB signalling. J Cell Mol Med 2018; 22(6): 3097-107.
[http://dx.doi.org/10.1111/jcmm.13587] [PMID: 29532994]
[183]
He X, Li C, Wu X, Yang G. Docetaxel inhibits the proliferation of non-small-cell lung cancer cells via upregulation of microRNA-7 expression. Int J Clin Exp Pathol 2015; 8(8): 9072-80.
[PMID: 26464649]
[184]
Wang Y, Dakhlallah D, Moldovan L, et al. Circulating MicroRNAs as Biomarkers: MicroRNA in Regenerative Medicine. Elsevier 2015; 1093-125.
[185]
Lu J-W, Hsia Y, Yang W-Y, et al. Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model. Carcinogenesis 2012; 33(1): 209-19.
[http://dx.doi.org/10.1093/carcin/bgr224] [PMID: 22021908]
[186]
Wu X, Li S, Xu X, et al. The potential value of miR-1 and miR-374b as biomarkers for colorectal cancer. Int J Clin Exp Pathol 2015; 8(3): 2840-51.
[PMID: 26045793]
[187]
Wang Y, Luo X, Liu Y, Han G, Sun D. Long noncoding RNA RMRP promotes proliferation and invasion via targeting miR-1-3p in non-small-cell lung cancer. J Cell Biochem 2019; 120(9): 15170-81.
[http://dx.doi.org/10.1002/jcb.28779] [PMID: 31050363]
[188]
Zhao Q, Zhang B, Shao Y, et al. Correlation between the expression levels of miR-1 and PIK3CA in non-small-cell lung cancer and their relationship with clinical characteristics and prognosis. Future Oncol 2014; 10(1): 49-57.
[http://dx.doi.org/10.2217/fon.13.242] [PMID: 24328409]
[189]
Yu QQ, Wu H, Huang X, et al. MiR-1 targets PIK3CA and inhibits tumorigenic properties of A549 cells. Biomed Pharmacother 2014; 68(2): 155-61.
[190]
Chiu KL, Lin YS, Kuo TT, et al. ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis. Oncotarget 2017; 8(29): 47365-78.
[http://dx.doi.org/10.18632/oncotarget.17648] [PMID: 28537886]
[191]
Jiao D, Chen J, Li Y, et al. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT. J Cell Mol Med 2018; 22(7): 3526-36.
[http://dx.doi.org/10.1111/jcmm.13629] [PMID: 29664235]
[192]
Jiang S, Zhang H-W, Lu M-H, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010; 70(8): 3119-27.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-4250] [PMID: 20354188]
[193]
Ovcharenko D, Kelnar K, Johnson C, Leng N, Brown D. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res 2007; 67(22): 10782-8.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-1484] [PMID: 18006822]
[194]
Gironella M, Seux M, Xie M-J, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 2007; 104(41): 16170-5.
[http://dx.doi.org/10.1073/pnas.0703942104] [PMID: 17911264]
[195]
Donnem T, Eklo K, Berg T, et al. Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J Transl Med 2011; 9(1): 6.
[http://dx.doi.org/10.1186/1479-5876-9-6] [PMID: 21219656]
[196]
Wang Y, Li J, Tong L, et al. The prognostic value of miR-21 and miR-155 in non-small-cell lung cancer: A meta-analysis. Jpn J Clin Oncol 2013; 43(8): 813-20.
[http://dx.doi.org/10.1093/jjco/hyt084] [PMID: 23817461]
[197]
Xue X, Liu Y, Wang Y, et al. MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN. Oncotarget 2016; 7(51): 84508-19.
[http://dx.doi.org/10.18632/oncotarget.13022] [PMID: 27811366]
[198]
Xu T-P, Zhu C-H, Zhang J, et al. MicroRNA-155 expression has prognostic value in patients with non-small cell lung cancer and digestive system carcinomas. Asian Pac J Cancer Prev 2013; 14(12): 7085-90.
[http://dx.doi.org/10.7314/APJCP.2013.14.12.7085] [PMID: 24460255]
[199]
Wang N, Guo H, Dong Z, et al. Establishment and validation of a 7-microRNA prognostic signature for non-small cell lung cancer. Cancer Manag Res 2018; 10: 3463-71.
[http://dx.doi.org/10.2147/CMAR.S170481] [PMID: 30254489]
[200]
Yang M, Shen H, Qiu C, et al. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer 2013; 49(3): 604-15.
[http://dx.doi.org/10.1016/j.ejca.2012.09.031] [PMID: 23099007]
[201]
Gao Y, Fu S, Jiang W, Li B, Tian Y, Fu X. Association of MiR-155 expression with prognosis in resected stage III non-small cell lung cancer. Chinese J Lung Cancer 2014; 17(5): 417-23.
[202]
Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: Discovery, function and future perspectives. Cell Death Differ 2010; 17(2): 215-20.
[http://dx.doi.org/10.1038/cdd.2009.69] [PMID: 19498445]
[203]
Chen F, Hou SK, Fan HJ, Liu YF. MiR-15a-16 represses Cripto and inhibits NSCLC cell progression. Mol Cell Biochem 2014; 391(1-2): 11-9.
[http://dx.doi.org/10.1007/s11010-014-1981-y] [PMID: 24500260]
[204]
Yang T, Thakur A, Chen T, et al. MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer. Tumour Biol 2015; 36(6): 4357-65.
[http://dx.doi.org/10.1007/s13277-015-3075-1] [PMID: 25874488]
[205]
Bozok Çetintaş V, Tetik Vardarlı A, Düzgün Z, et al. miR-15a enhances the anticancer effects of cisplatin in the resistant non-small cell lung cancer cells. Tumour Biol 2016; 37(2): 1739-51.
[http://dx.doi.org/10.1007/s13277-015-3950-9] [PMID: 26314859]
[206]
Bandi N, Zbinden S, Gugger M, et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 2009; 69(13): 5553-9.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-4277] [PMID: 19549910]
[207]
He J. Knocking down MiR-15a expression promotes the occurrence and development and induces the EMT of NSCLC cells in vitro. Saudi J Biol Sci 2017; 24(8): 1859-65.
[http://dx.doi.org/10.1016/j.sjbs.2017.11.028] [PMID: 29551936]
[208]
Ergun S, Güney S, Temiz E, Petrovic N, Gunes S. Significance of miR-15a-5p and CNKSR3 as novel prognostic biomarkers in non-small cell lung cancer. Anticancer Agents Med Chem 2018; 18(12): 1695-701.
[http://dx.doi.org/10.2174/1871520618666180718100656] [PMID: 30019650]
[209]
Yang FR, Li HJ, Li TT, Zhao YF, Liu ZK, Li XR. Prognostic value of MicroRNA-15a in human cancers: A meta-analysis and bioinformatics. BioMed Res Int 2019; 2019: 2063823.
[http://dx.doi.org/10.1155/2019/2063823] [PMID: 31061821]
[210]
Li J, Li M, Gao F, Ge X. Serum microRNA-15a level acts as a potential diagnostic and prognostic biomarker for human esophageal squamous cell carcinoma. Cancer Biomark 2017; 18(1): 11-7.
[http://dx.doi.org/10.3233/CBM-160667] [PMID: 27802201]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy